JP2021511298A5 - - Google Patents

Info

Publication number
JP2021511298A5
JP2021511298A5 JP2020538029A JP2020538029A JP2021511298A5 JP 2021511298 A5 JP2021511298 A5 JP 2021511298A5 JP 2020538029 A JP2020538029 A JP 2020538029A JP 2020538029 A JP2020538029 A JP 2020538029A JP 2021511298 A5 JP2021511298 A5 JP 2021511298A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
siglec
variable region
region containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020538029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511298A (ja
JP7342005B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/013316 external-priority patent/WO2019140273A1/en
Publication of JP2021511298A publication Critical patent/JP2021511298A/ja
Publication of JP2021511298A5 publication Critical patent/JP2021511298A5/ja
Application granted granted Critical
Publication of JP7342005B2 publication Critical patent/JP7342005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020538029A 2018-01-11 2019-01-11 エフェクター機能が減少した抗siglec-7抗体 Active JP7342005B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616317P 2018-01-11 2018-01-11
US62/616,317 2018-01-11
PCT/US2019/013316 WO2019140273A1 (en) 2018-01-11 2019-01-11 Anti-siglec-7 antibodies having reduced effector function

Publications (3)

Publication Number Publication Date
JP2021511298A JP2021511298A (ja) 2021-05-06
JP2021511298A5 true JP2021511298A5 (cg-RX-API-DMAC7.html) 2022-02-07
JP7342005B2 JP7342005B2 (ja) 2023-09-11

Family

ID=67219179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538029A Active JP7342005B2 (ja) 2018-01-11 2019-01-11 エフェクター機能が減少した抗siglec-7抗体

Country Status (6)

Country Link
US (1) US11912766B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737410A4 (cg-RX-API-DMAC7.html)
JP (1) JP7342005B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019208025A1 (cg-RX-API-DMAC7.html)
CA (1) CA3087968A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019140273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20250035502A (ko) * 2022-03-31 2025-03-12 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Siglec-7을 표적으로 하는 이중특이적 자연 살해 인게이저
KR20240168432A (ko) * 2022-03-31 2024-11-29 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 인간 Siglec-7에 대한 항체 및 이의 면역요법을 위한 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120815A2 (en) 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
AU2008272330A1 (en) 2007-07-04 2009-01-08 Forerunner Pharma Research Co., Ltd. Anti-Muc17 antibody
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
ES3066738T3 (en) * 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
ES2861313T3 (es) * 2014-08-07 2021-10-06 Daiichi Sankyo Co Ltd Anticuerpo anti Orai1
JP2017532025A (ja) 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 交差反応性siglec抗体
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
MX2018006072A (es) * 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
AU2017207807A1 (en) 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
CN108699158B (zh) * 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
IL264674B2 (en) * 2016-08-05 2023-09-01 Allakos Inc Antibodies to siglec7 for cancer treatment

Similar Documents

Publication Publication Date Title
US12152076B2 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US12180302B2 (en) Heterodimeric antibodies that bind fibroblast activation protein
JP2024119791A5 (cg-RX-API-DMAC7.html)
JP2024009818A5 (cg-RX-API-DMAC7.html)
JP2022544760A5 (cg-RX-API-DMAC7.html)
JP2023528350A5 (cg-RX-API-DMAC7.html)
CN108699136A (zh) 结合cd3和psma的异二聚抗体
JP2020522266A5 (cg-RX-API-DMAC7.html)
CN107406512A (zh) 结合cd3和cd38的异二聚体抗体
AU2014296215A1 (en) Stabilization of Fc-containing polypeptides
CA3025310A1 (en) Compositions and methods related to engineered fc constructs
AU2018358883A1 (en) Method for in vivo generation of multispecific antibodies from monospecific antibodies
JP2024521131A5 (cg-RX-API-DMAC7.html)
US20220119549A1 (en) Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
JP2022513999A5 (cg-RX-API-DMAC7.html)
JP2024535712A5 (cg-RX-API-DMAC7.html)
JP2023541816A5 (cg-RX-API-DMAC7.html)
JP2023523016A5 (cg-RX-API-DMAC7.html)
JP2023554097A5 (cg-RX-API-DMAC7.html)
JP2024535705A5 (cg-RX-API-DMAC7.html)
US20240150471A1 (en) Natural killer cell antibodies with increased adcc activity
AU2024251862A1 (en) Anti-cd28 x anti-enpp3 antibodies
JP2025507448A5 (cg-RX-API-DMAC7.html)
US20240247062A1 (en) Heterodimeric antibodies that bind claudin18.2 and cd3
JP2024534034A5 (cg-RX-API-DMAC7.html)